Korea Investment Partners

Bio Design Lab is a biotechnology company focused on the development of biopharmaceutical products, specifically in the areas of gene, cell, and immunotherapies. The company employs systems-level genetic and genomic design strategies to create potent drugs aimed at addressing a range of diseases. By utilizing advanced methodologies, Bio Design Lab aims to enhance the efficiency of drug development processes for healthcare organizations, ultimately contributing to the creation of effective therapeutic solutions.

Syntekabio, Inc. is a bioinformatics company based in Daejeon, South Korea, founded in 2009. The firm specializes in genome analysis and the integration of bio data, utilizing advanced algorithms to create personal genome maps that facilitate disease prevention and the development of customized medications. Syntekabio also offers a technology for collecting and integrating decrypted whole genome data, which is instrumental in analyzing diseases, including rare conditions. Their MAHA supercomputer significantly reduces data-processing costs and enhances genome-based diagnostics. The company focuses on gene-related research and technology development, leveraging a genome big data platform and artificial intelligence for drug development and genetic analysis.

PulseSight Therapeutics is an ophthalmology-focused biotechnology company developing treatments for severe retinal diseases. It advances non-viral gene therapies delivered through minimally invasive methods to address blindness associated with retinal conditions. In addition, the company develops therapeutic proteins aimed at treating both short- and long-term retinal disorders, including chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases, and macular edema. These approaches seek to improve ocular bioavailability and tolerability while supporting adherence to treatment. By focusing on therapies that preserve and improve vision, PulseSight aims to provide physicians and ophthalmologists with options that address unmet clinical needs and improve patient quality of life.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Geninus is a biotechnology company specializing in clinical genome analysis solutions tailored for precision medicine clinics. By leveraging advanced genomic technologies, Geninus aims to enhance the accuracy and effectiveness of personalized medical treatments. The company focuses on delivering innovative tools and insights that facilitate the interpretation of genetic data, ultimately supporting healthcare providers in making informed decisions for patient care. Through its services, Geninus contributes to the evolving landscape of precision medicine, promoting better health outcomes through individualized approaches to treatment.

Medizen Humancare, founded in 2012 and headquartered in Seoul, South Korea, is a research company specializing in genomic analysis to predict individual disease risks. The company offers services such as M-CHECK, which analyzes patients' genetic risk for specific diseases using gene chips or analysis kits, and MELTHY (DTC), a DNA analysis service. Medizen Humancare's work involves acquiring disease-specific genome contents, identifying new drug candidate genes, and developing preventive measures, with a focus on guiding disease prevention and extending healthy life spans through personalized genetic insights.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Founded in 2011, Gencurix is a South Korean company specializing in the development of molecular diagnostic products to support precision medicine. Its portfolio includes prognostic tests for breast cancer (GenesWell BCT) and lung cancer (GenesWell ddEGFR Mutation Test), as well as companion diagnostics for lung cancer.

Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.

Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.